Vertex Pharmaceuticals

  • Want Multi-baggers? Then Consider These 3 Biotech Companies

    By Greg Williamson - August 15, 2013 | Tickers: CELG, EXEL, VRTX

    In after hours trading on April 18th, a few hours after the release of my previous article (2 Biotech Companies With Multi-bagger Potential) focusing on Exelixis (NASDAQ: EXEL), Vertex Pharmaceutical (NASDAQ: VRTX), and Celgene (NASDAQ: CELG), Vertex's share price increased over 60%, due to positive data on its approved cystic fibrosis drug Kalydeco combined with VX-661, its high-potential cystic fibrosis drug candidate. This combination provides an improved lung function more »

  • Gilead Races against Competitors for an Oral Hepatitis C Cure

    By Todd Campbell - August 13, 2013 | Tickers: ABBV, GILD, MRK, VRTX

    The search for a hepatitis C cure is one of the most active areas within biotechnology research and development.

    One of the company's ushering in the next generation of hepatitis C treatment is Gilead Pharmaceuticals (NASDAQ: GILD). The company acquired hepatitis C drug sofosbuvir in its $11.2 billion acquisition of Pharmasset back in January 2012.

    Sonosbuvir has a very good chance of beating rival drugs to the market more »

  • This Biotech’s Cystic Fibrosis Treatments Could Catapult It To Profitability

    By Leo Sun - July 31, 2013 | Tickers: BMY, GILD, JNJ, VRTX

    Cystic fibrosis (CF), a genetic disorder that affects the lungs, the pancreas, liver, and intestine, is the second most common inherited disorder in the United States, after sickle cell anemia. More than 30,000 Americans are currently diagnosed with CF, and an average of 1,000 new cases surface annually. One in 3,700 births is believed to have the defective CF gene, and it is estimated that more than more »

  • 3 Key Takeaways From JNJ's Q2

    By Brandy Betz - July 18, 2013 | Tickers: LLY, JNJ, VRTX

    Johnson & Johnson (NYSE: JNJ) reported its second quarter on Tuesday, and turned in some positive numbers. Revenue grew 8.5%, year-over-year, up to $17.9 billion. The EPS was higher than analyst estimates, and the company upped its full-year guidance.

    But the details are where things get interesting. Here are three key takeaways from the earnings report -- and what they mean for Johnson & Johnson’s future.

    1. Infectious disease and more »

  • Is The Orphan Drug Buying Frenzy Over?

    By Ben Williams - July 17, 2013 | Tickers: ACAD, AEGR, ALXN, ONXX, VRTX

    Orphan drug stocks may have been the hottest and best performing sector of the market for the past year, but they have really been on fire for the past month and have frequently been the object of takeover rumors. The big question is, “Can this buying frenzy be sustained; or is the rally over, at least for the time being, now that orphan drug stocks appear to be leveling off more »

  • Pharmaceuticals: 1 Short, 1 Buy, 1 Strong Buy

    By Mohsin Saeed - July 16, 2013 | Tickers: AXDX, LFVN, VRTX

    Biotechnology stocks are usually valued on the potential of their pipelines, especially if there is no drug already in the market. The 'patent-cliff' has increased the investor interest in promising pipelines, improving the valuations of small biotechnology companies. The increase in FDA approvals has also positively impacted the entire healthcare sector by encouraging investors to invest more heavily in pipeline stories.

    A number of biotechnology companies have benefited from this more »

  • Can These Companies Continue Their Bull Run?

    By Madhukar Dubey - June 27, 2013 | Tickers: HPQ, MSFT, SNE, TMUS, VRTX

    When the stock price of a company increases significantly, investors are curious to know whether it is likely to increase further. High growth in a short time might make investors skeptical about further growth potential of the stock. However, there are some stocks which have further growth potential. Here are three companies that have registered more than 70% YTD growth in their stock prices.

    Source: Google Finance

    In order to more »

  • Inside HCV: An Interview with Janssen

    By Brandy Betz - June 12, 2013 | Tickers: GILD, JNJ, VRTX

    Our job here is to examine companies through an investing perspective. But in churning out numbers and comparing potential product sales, we sometimes overlook the human element. Right now, the Food and Drug Administration is on the cusp of approving two hepatitis C drugs that could revolutionize patient cure rates.

    I recently discussed simeprevir, the promising HCV candidate from Johnson & Johnson (NYSE: JNJ) subsidiary Janssen. The drug achieved impressive cure more »

  • 3 Significant Insider Sells in Healthcare Worth Noting

    By Brian Nichols - May 31, 2013 | Tickers: BMRN, REGN, VRTX

    It’s no secret that the insiders of a company know what’s happening before us. They know trends, demand, supply, and to most of us, it makes no sense for an executive to sell shares prior to a large takeover or raised earnings guidance. Thus, when an insider sells shares we automatically assume the worst – and in some cases – we are correct!

    Two Examples of Insider Selling

    While investors more »

  • 4 Companies Riding the Orphan Drug Rocket

    By Cory Renauer - May 30, 2013 | Tickers: ALXN, CELG, NVS, ONXX, VRTX

    A recent report by EvaluatePharma claims that sales of orphan drugs -- ones that target rare diseases -- will grow at twice the rate of the overall prescription market. Pharmaceutical giant Novartis (NYSE: NVS) was the largest seller of orphan drugs in 2012, and will likely be the number one in 2018 with expected sales of $11.8 billion, but that's not where I would put my money.

    Over the last more »

  • Did This Stock Deserve This Sudden Upward Swing?

    By Jeremiah Feliciano - May 8, 2013 | Tickers: MNKD, NVS, VRTX

    Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged from $52.87 on April 18 to a 12-year high of $85.90 per share on April 19 after the company reported positive outcomes from the Phase II clinical trial of its experimental drug, VX-661. Last time the stock witnessed such as rapid growth was on November 3, 2000, when the prices reached $93.87 a share.

    It’s only Phase II

    The drug more »

  • Double-Digit Returns from the Biotechnology Strategy

    By Jeff Stouffer - May 7, 2013 | Tickers: NPSP, REGN, SNY, XBI, THRX, VRTX

    Investments in biotechnology by the average investor tend to deliver hit or miss returns over time. Since inception, the SPDR S&P Biotech ETF (NYSEMKT: XBI) has delivered double-digit returns. This ETF holds 53 stocks and is focused on this industry. Created on Jan. 31, 2006, the one-year return is 33.76%, the three-year return is 23.57%, and the five-year return is 13.27%. Only the one-month and three-month more »

  • Top Three Performing NASDAQ 100 Stocks for 2013

    By Naomi Warmate-Igwe - May 1, 2013 | Tickers: CELG, LIFE, VRTX

    It should come as no surprise that year to date, the top three performing NASDAQ 100 stocks come from companies in the health care sector. Through April 26th, those companies were Vertex Pharmaceuticals (NASDAQ: VRTX) Celgene Corporation (NASDAQ: CELG) and Life Technologies (NASDAQ: LIFE). As many analysts have predicted, the health care sector is performing exceptionally in 2013, asU.S. firms scramble for their piece of the pie in more »

  • 3 Healthcare Picks From Janus Fund

    By Reuben Brewer - April 30, 2013 | Tickers: ESRX, PRGO, VRTX

    Janus Fund (JANDX) bares the name of the fund family behind it. The flagship offering focuses on growth. Three healthcare stocks that underperformed for the fund in 2012 still appear to have growth potential.

    Growth

    Janus Fund focuses on growth. In its search for companies with “earnings growth potential that may not be recognized by the market at large,” management starts at the ground floor. Building its research and portfolio more »

  • This Biotech Just Popped, and Might Pop Further

    By Terry Chrisomalis - April 29, 2013 | Tickers: GILD, MRK, VRTX

    Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have appreciated significantly in 2013 so far, and it seems that the trend might continue for the rest of the year. Vertex is a biotech company focused on treating rare diseases with limited treatment options. Vertex has popped big recently on new promising data for patients diagnosed with Cystic fibrosis. 

    Cystic Fibrosis is a rare disease that causes thick mucus to build up in more »

  • Orphan Drug Biotechs Do It Best

    By Terry Chrisomalis - April 19, 2013 | Tickers: ALXN, BMRN, VRTX

    There are many biotech stocks to choose from that have long-lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drugs. You might ask why you should bother investing in this type of biotech stocks? Because these companies treat rare diseases with limited treatment options. 

    In my opinion, these biotech stocks perform better than their peers, and will more »

  • 2 Biotech Companies With Multi-Bagger Potential

    By Greg Williamson - April 18, 2013 | Tickers: CELG, EXEL, VRTX

    Some investors consider speculation to be a dirty word, but it can be an important component of a diversified portfolio. Although speculative stocks have an increased level of risk, they also have enormous reward potential. The following four keys will allow you to improve your chances of hitting a home run with speculative stocks, while ensuring that your portfolio is protected:

    1.) Limit your speculative holdings to between 10% to more »

  • Orphan Drug Biotechs Do It Best

    By Terry Chrisomalis - April 16, 2013 | Tickers: ALXN, BMRN, VRTX

    There are many biotech stocks to choose from that have long lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drug status. You might ask why invest in these types of biotech stocks? It is quite simple really, these types of companies treat rare diseases with limited treatment options. 

    In my opinion I feel these biotech stocks more »

  • Monday’s Market Moving Downgrades Worth Noting

    By Brian Nichols - April 10, 2013 | Tickers: CA, JNJ, VRTX

    Stocks can be pushed higher or lower as analysts provide their outlooks. These calls are not enough to make an investment, but should be considered as part of your research. Therefore, I am assessing a few of Monday’s top downgrades, and determining if each was a good call.

    Johnson & Johnson (NYSE: JNJ)

    Shares of Johnson & Johnson fell lower by 1.50% on Monday after JPMorgan downgraded the stock to more »

  • Monday’s Market Moving Downgrades Worth Noting

    By Brian Nichols - April 8, 2013 | Tickers: CA, JNJ, VRTX

    Stocks can be pushed higher or lower as analysts provide their outlooks. These calls are not enough to make an investment, but should be considered as part of your research. Therefore, I am assessing a few of Monday’s top downgrades, and determining if each was a good call.

    Johnson & Johnson (NYSE: JNJ)

    Shares of Johnson & Johnson fell lower by 1.50% on Monday after JPMorgan downgraded the stock to more »

  • Page 1 of 3